BeOne’s bargain-basement VEGF multispecific

While many deals involving anti-PD-(L)1 x VEGF multispecifics have made headlines for their meaty valuations, some companies have preferred to shop in the bargain basement. The latest to pursue the budget route is BeOne, which last week paid $20m for rights to a molecule coded HH160, originated by the Chinese company Huahui Health, it has emerged in a Hong Kong stock exchange filing. This is reminiscent of Instil Bio paying just $10m up front for ImmuneOnco’s anti-PD-L1 x VEGF MAb palverafusp alfa, at a time when Merck & Co, Pfizer and Bristol Myers Squibb were shelling out $500m to $1.5bn for similar bispecifics. HH160 adds a third target into the mix, being described in an AACR 2025 poster as a “symmetrical hexavalent trispecific targeting PD-1, CTLA-4 and VEGF-A”, constructed by fusing anti-PD-1 and anti-CTLA-4 nanobodies to the heavy chain of an anti-VEGF-A human IgG1 antibody with a silent Fc region. Whether this enhances efficacy, increases dosing convenience and reduces side effects has yet to be shown, as HH160 is still in preclinical trials. One note of caution is that Instil’s own bargain-basement journey didn’t end well: palverafusp was handed back to ImmuneOnco in January.